HGEN: Weekend Before Phase III DataHGEN has two RCTs with imminent data, one of them the company's own, the other the NIH's ACTIV-5 Trial. The company is preparing to file an EUA for Lenzilumab pending the trials' completion. Announcements are expected in the week starting March 29, two days from now. Nomis Bay, a fund that had held a large stake of HGEN since it was trading in single digits unloaded millions of shares in the weeks leading up to now. The fund still holds between 9% and 10% of the outstanding shares.In conferences throughout March, HGEN executives mainly showcased the potential for Lenz as a COVID therapeutic, and differences between their trial designs and those of other, failed monoclonal antibodies. I hope everyone is sized appropriately, whether long or short. This stock could make some very large moves soon.
Coronavirus (COVID-19)
Short SPYLooks like downtrend continuation. Looking to retest lows, and possibly break out to the downside. Trade on with stops above recent highs.
Despite short term rally, looking to sell short SPYMarket is rallying as expected after such a bloodletting. I don't think the bottom is in yet. Heavy volume on todays doji candle could be a sign of further downside. If market breaks recent low, I will add more to my short position. Alternately, market could rally up into moving average resistance offering a better short entry. Be careful, there is extreme volatility and the news could change things on a dime. Be well
Largest Single Day Spike in Worldwide Coronavirus Cases & DeathsToday records the largest single day spike in worldwide coronavirus deaths, at over 60,000 new deaths reported. The same is true with a massive surge in new cases worldwide, brought on by new variants of covid-19 from UK and South Africa.
Sao Paolo, Brazil has alone reported a record 1021 deaths within a 24 hour period:
www.reuters.com
Germany is implementing its strictest lockdown yet due to a rise in cases from the B.1.1.7+E484K UK variant of the virus. This variant is more lethal, longer lasting, and more infectious. It's possible that even supermarkets will close during Merkle's April lockdown:
www.spiegel.de
Covid cases have also risen by 5% in at least 27 states in the US:
www.cnbc.com
CDC officials are warning of an avoidable new surge in cases here in the US if measures to mitigate are lifted too soon; as states like Texas and others re-open to full capacity or with few restrictions.
www.axios.com
Pfizer and Moderna reports vaccinations are highly effective in preventing multiple UK variants, including B.1.1.7, but indicates a drop in efficacy towards preventing the South African variant:
www.nejm.org
The race to vaccinate ramps up along with a ramp up in viral transmission, as well as new variants spreading across the world. Essentially it appears we are nearing the finish line, but fighting our toughest battle yet to defeat the virus.
Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic and Medytox To Develop Vaccines Against COVID-19 Variants
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.
Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines)
Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful
Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox
finance.yahoo.com
$SPCB Wins COVID-19 Quarantine Project $3 Million per MonthSuperCom Wins COVID-19 Quarantine Compliance Project with the Israeli Government Valued at an Estimated $3 Million per Month in Recurring Revenues
Initial project term of 3 months, with potential extension for up to 36 months
This nationwide project is expected to commence next week, along with contract signing, for an initial term of 3 months, with an option to be extended for up to 36 months. The project is billed at a per-unit per-day rate is expected to generate approximately $3 million per month in recurring revenues for SuperCom. However, revenue may increase or decrease based on actual usage.
finance.yahoo.com
BAVA - LongFundamental and Technical Analysis show this as a very strong buy candidate. I can see this hitting 930.00 within 8 Weeks.
HALBERD CORPORATION· Current Price – $0.0419
· Best Case Scenario PT over 1$
· Market Cap – $11 million
· Debt – 0
Halbert Corporation
Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the technology to cure diseases like, Covid-19, PTSD, Cancer, CTE, tuberculosis, malaria, strokes and heart attacks, blood sepsis, Alzheimer’s Disease.
In the last 8 months they have secured 7 provisional patents (which give the global rights) to technology of treating severe Covid-19 patients, Covid-19 nasal spray, antibody cocktail to boost immune system against Covid - 19 and recently developed two new antibodies that no other big pharma has, which allows them detect Covid-19 in matter of minutes using saliva or blood samples. Furthermore, are working with $GRPS to develop anti-addiction patches (alcohol, drugs, nicotine).
To achieve their further goals they have carefully selected to partner with Arizona State University (who have won the first place in innovation for the last 6 years going in the USA, higher than MIT or Stanford). This partnership has already delivered amazing milestones and they are already working towards filing for new joint provisional patents. Halbert has 0 debt, yes ZERO and been receiving funding in 2 million chunk donations due to promising results. Halberd’s corporate charter also prohibits them from issuing any kind of convertible financial instrument, debt or preferred stock, however the corporation shall be able to issue warrants or options.
Management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.
Furthermore, the ultimate catalyst, which seems quite likely is for Halbert to partner or licence their technology to one of the big pharma as the CEO, William has mentioned so on multiple occasions. In the past, he has been approached by the big pharma (Pfizer and Novartis), and hopes the same will happen with their revolutionary technology.
Issued Patents
2014 - Sequential Extracorporeal Treatment of Bodily Fluids
2015 - Utilization of Stents for the Treatment of Blood Borne Carcinomas
Provisional Patents
11/2020 - Fluorescent Antibody’s in Covid-19 Detection & Treatment
10/2020 - Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).
10/2020 - Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus
09/2020 - Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans
04/2020 - Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus
04/2020 - Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients
03/2020 - Method for Treating and Curing Covid-19 Infection
Future Patents
During podcasts and interviews the CEO said he will announce another 2 patents soon. They are waiting to achieve provisional status to ensure the technology is safe. Further patents are in the pipeline as CEO’s devised a strategy to secure as many patents as they can, of which they could then either licence or partner on developing on joint ventures with big pharma.
Upcoming Catalyst 2021
· 2 patent provisional applications yet to be announced
· Development of antibody cocktail vitamins to boost immune system against Covid-19 (Q2 launch and start to generate revenue)
· Development of Covid-19 Nasal Spray
· Commercial development of Covid-19 test using saliva or blood (takes only a minute no nasal swap which is uncomfortable)
· Patent Licencing to other pharma companies – they produced antibodies that are stronger than some of the big pharma
· Partnerships and joint ventures with other organizations
· Discovery of new treatments and patent fillings
· Further development of extracorporeal technology to treat cancer, PTSD, Alzheimer’s, blood sepsis, CTE
· Anti-addiction patches
Sociability Factor
In penny stock market, especially during current times (rise of social media and social traders) the CEO’s or the organization being sociable, sharing achievements, milestones, ethos and so on can have a massive impact on the share value. In this regard, Halberd’s corporation in my view would score high points. They tend to release anywhere between 2/5 press releases a month in which various milestones would be announced via text, video interviews or podcasts.
Senior Leadership Team
The CEO’s aim was to ensure that they develop a very cohesive team of talented people to achieve greatness. Here below I have listed a few KEY members including bio snapshots.
Business Advisory Board
The CEO – based on the videos and podcasts that are available (6+) of William A. Hartman sounds very ambitious and driven on a mission to be the best in the industry and revolutionize medicine.
He believes Halberd corporation share value should be worth $1 per share. This may sound like very ambitious venture for some, however, let us not forget he founded and headed separate business group within TRW Automotive with plants in the U.S., Mexico and Europe that produced combined annual sales of $1.3 Billion – this shows extreme capability. He has also worked as COO for Nanologix, Inc, President and CEO of Premier Biomedical. I would recommend checking out any of his interviews to feel his passion.
Carl Eller - retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association, was drafted in 1964 as the league’s 6th pick overall by the Minnesota Vikings, he became a major factor as a defensive end with the unit known as the “Purple People Eaters.” Eller became a six-time Pro Bowl player who appeared in four Superbowls and is currently focused on helping former players transition into retirement.
Alec Torelli - is an entrepreneur, author, motivational speaker and professional poker player who has worked with various companies to apply his life experiences/lessons from poker, in a practical manner, to carry out their corporate visions, increase sales and/or improve service delivery while creating meaningful lives for their employees.
Scientific Advisory Board
Mitchell S. Felder, MD - is a prolific inventor. He is a Board Certified Neurologist and former CEO, President, Chairman and founder of Infectech and Nanologix, and currently serves as Locum Tenens Attending Neurologist with UPMC Pennsylvania
Dr. Felder has authored or co-authored six publications, three studies and has currently 21 issued patents. Dr. Felder was the Acting Chief of the Department of Neurology, Sharon Regional Health System from 1989 until 2001. Dr. Felder served as the Acting Chief of the Department of Neurology at the William Beaumont Army Medical Center in 2011.
Dr. Qiang (Shawn) Chen, who is the Principal Investigator at ASU, in charge of the research and development for Halberd Corp:
Take a look at his research projects over the last 4-5 years and you see why this HALB/ASU cooperation is a marriage made in heaven. Only weeks ago, Halberd signed another R&D-agreement with GreenBioAZ inc, it's a start up from Arizona State University and will do research for Halberd's radiofrequency technology. Dr. Chen is CEO of GreenBioAZ
Patricio Reyes, MD, FAAN - a board certified neurologist and neuropathologist, and Chief of Neurology/TBI/Alzheimer’s Disease/Cognitive Disorders at the VA Medical Center in Phoenix, Arizona and is a Board Member of the Retired National Football League Players Association. Dr. Reyes is a board member, and former Chair of the Education Committee and 2009 Distinguished Educator of the Association of Ringside Physicians. HALB has access to the VA Hospital Group because of Dr. Reyes.
Timeline of Key Press Releases
I have gone through the list of all of their press releases (they post regularly) and compiled key updates here below:
April 6, 2020 - Halberd announces agreement to retire 192,000,000 outstanding common shares and reduced authorized shares of common stock to 1,000,000,000.
April 8, 2020 – Halberd, Premier Biomedical ($BIEI) and Gold River Productions ($GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch.
July 1, 2020 - Halberd establishes United Kingdom subsidiary to facilitate access to European research facilities and markets to establish a global footprint.
July 13, 2020 - Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt, or preferred stock.
August 4, 2020 - Halberd secures $2 Million for Covid-19 Research
August 31, 2020 - Halberd signed an agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments.
September 21, 2020 - Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen
September 24, 2020 - Successful creation of a fluorescent antibody, that will help them create a rapid Covid-19 test using saliva or a drop of blood. This approach will allow for accurate test results in a matter of minutes – believe travel industry may benefit from this approach.
October 8th, 2020 – CEO’s letter of updates and accomplishments
October 13, 2020 – Halberd and ASU Develop Antibody Against Covid-19, pursuing new joint patent.
October 19, 2020 – in process to filing a new joint patent with AUS for creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. This protein will allow extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood.
October 29, 2020 – Strategic plan curing blood sepsis, Alzheimer’s Disease, Heart Attack and Stroke using extracorporeal process
November 12, 2020 – Patent pending for Covid-19 detection test from saliva or blood in minutes.
December 1, 2020 – Halberd re-organizes advisory board.
December 17, 2020 - Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19
December 23, 2020 - Halberd Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein – “Mathematically speaking, if each is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives is substantially reduced when antibodies work in tandem”
January 4, 2021 - Halberd Corporation 2020 Year End CEO Letter, looking forward to 2021
January 14, 2021 - Halberd Develops Medication to Boost Immune System Against Covid-19
February 16, 2021 - Halberd has engaged GreenBioAZ to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease.
March 2, 2021 - Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater - “We are excited about the progress being made in developing Halberd’s effective proprietary antibodies against Covid-19. These results put our antibody in the same realm of effectiveness as the best-known competitive SARS-COV-2 antibodies.
Since posting links may take an excessive amount of space here, you can find all the press releases here and search by date, plenty more to see that are not included in my post -
Hope people found this helpful and I look forward to seeing what the future holds for $HALB!
OCGN not AZNNot good news for AZN's 'not vaccine' recently as "Denmark and Norway Suspend Use of AstraZeneca Vaccine Over Blood Clot Worries" could this be good news for OCGN, I would like to think yes. What are your thoughts?
Hit that link in my bio for your own charts like this.
Teladoc Health Ready For A Rally! 🩺TDOC had a massive $133 correction since February 16th. They reported an earnings of -$3.07 which missed estimates of $0.24. Big miss on their earnings accompanied with a correction in the overall market resulted in price landing below $200. The past 4 days TDOC reached a low of $174 and today managed to test the $200 support but failed to get above. I have entered 4/16 $220 calls at close today avg $ of $7.15. Will look to add more TDOC swings on continued show of strength. Over $200/202 TDOC can make a move back to $220 quickly if the market holds up.
Chart:
HVN: HVN at ~$195 serving as a strong support zone. This is where TDOC can chop around at if it isn’t ready to break $201/202 lvl yet. HVN at $217/220 area serves as first PT.
Fib: Fib retracement lvls at $201.5 and $222 serving as good entries/exits.
Support/Resistance: Resistance levels roughly at $200,210, 216, and 221 lvls to play off of as well.
EMA’s: 20 EMA will be right at 223 on the Daily chart
MACD & RSI: both are gearing up for reversals
Plan: I entered a smaller position and would like to add heavier on confirmation of a move back to $220 PT.
SL: Will be watching $188-$190 lvl to hold as support for SL if we re-trace. Current AH price action has TDOC above $200 but lets see what it does Friday.
Battle of the mRNA vaccines.Just interesting that Moderna (MRNA) was taking off while Pfizer (PFE) was declining.
Long PFEBull Flag + Good prices call contracts NS Options? This may end with a price of 40 usd by the end of may
CopperThe Copper after COVID-19 underwent changes, this utility metal use in Electronic devices, Telecom industries, Kitchen appliance and … . due to quarantine and preferring online jobs and increasing communicating between firms via internet and working from home, The online businesses and works developed and the producing Electronic instruments and telecom infrastructures raised.
Now we are in highest value for this metal and countries started to vaccination of all people, So it seems be better for traders to going to short. I think it will has a correction during the next couple of weeks.
4.9 millions COVID cases by April 2021 in FranceOct 17 2020 = 21189 cases/day = 148323 cases/week
Oct 24 2020 = 31329 cases/day = 219303 cases/week
Oct 31 2020 = 40161 cases/day = 281127 cases/week
Nov 07 2020 = 56377 cases/day = 394639 cases/week
-379W H A T????????????????!!!!!!!!!! -379 deaths????
people are coming back to life now? Can anybody explain this??????
COVID-19 RecoveryBT has been operating on full steam since lockdown and with Key-Worker status they are still performing well. Reaching new highs on the basis of post-lockdown hope we should start to see a steady incline. Once we reach and break past 150 with even more market positivity, tied in with 5G releases and technology, we could see this being the new support floor.
SUNPHARMA Can witness Free unadulterated FallThe stock is weak and more so it has been exposed to the shock of heavy volume price level and now facing rejection at higher level. Let it cross 604.20 level then we can take the trade to ride the profit.
Covid vaccine may see positive effects on Gold through Mar@Apl I did initially see a possible start of the precious metal moving back to the main trend pre-end of March, as price began to settle around 1800, a sudden push south the last 7 days may be further indication of a more momentum related push north to return to the trend line from 2018, my long term view did show this dip, (see linked chart below), but with less strength and moving through March, as my thoughts were covid related, (very stupid of me), and not bank and previous market action, this push south during February may see March and April moving north, with potential for further continuation through May and June,
areas to watch for are 1728, 1740, 1762, 1800, 1828, 1858 and 1900, 1926 and 1932
For further information about my analysis please feel free to message me.
TDOC consolidation here at supportSaw nice level of support keep this stock from moving further to the red. If it finds its legs and shows more strength I will wait to enter calls at this area of value. No entry for me unless I see a break of that trendline showing a reversal. I like to be somewhat conservative on my trades - Dont fight the trend..
Fluidigm is the leader in mass cytometry and microfluidicsGreetings
Summary:
Fundamental Analysis:
Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative.Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies
Fluidigm is a leader in mass cytometry. According to market research and Fluidigm, the mass cytometry market reached 2.7 billion with CAGR at 26% by 2025.
The Biden administration plans to spend about $ 1.6 billion on expanding Covid-19 testing programs.
Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China.According to company and third-party estimates, the addressable market for flow cytometry analysis in blood cancer in China is approximately $100 million for 2021–2023, and is growing at a double-digit rate.
The company shows stable revenue growth from year to year.
Technical analysis:
From March 2020 to the end of September 2020, the 5th wave movement was completed.After that, a correction began, namely a double three, consisting of 2 zigzags.
At the moment, the company's shares are in the oversold zone according to the RSI indicator.
The company has several open gaps, namely in the following areas: $ 10-11, $ 15-19, $ 30-36 per share.
At the moment, the company's shares are at a strong support level.
Disclosure: I am/we are long FLDM.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.
Covid-19 Deaths US. P-Modeling Pt Z. Wavefunction Roots of CajunWelcome Hyperspace Travelers,
I have some very bad news.. Covid-19 is not done yet, far from it actually.
I am under the diagnostic impression based on recent literature publication that their is going to be a freakish mutation somewhere in the spike protein mechanic increasing virility and death rate.
I have pathed Three Wavefunction Roots.
Each Root is grounded in a linear domain.
Curvatures of each root are grounded by cyclical domain, supported by linear domain.
According to the wavefunction roots:
The worst case scenario has a slope of 75 degrees from Kinetic 0.
The second worst case scenario has a slope of 66 degrees from Kinetic 0.
The best case scenario has a slope of 30 degrees from Kinetic 0.
Kinetic 0 is the pivot between one wavefunction root to another and is bound to the (x,x) (x,x) coordinate that has unstable equilibrium. Correction of equilibrium is dependent upon a parabola. Velocity and Amplitude are determined by the rate at which the parabola equalizes to Net 0, called kinetic decay.
Each path is color color coded and lettered for your viewing pleasure so you can understand the severity of what we are about to encounter.
A\ :: slope of 75 degrees would be catastrophic for first responders and the healthcare system. It would collapse under the extraordinary prolonged pressure.
B\ :: slope of 66 degrees would also be catastrophic for first responders and the healthcare system. It would be on the verge of imminent collapse.
C\ :: slope of 30 degrees would keep the entire system in the green and represents the absolute best case scenario, IF WE CLOSED DOWN TODAY.
Unfortunately, we won't close down today. Or tomorrow. Because humans like learning things the hard way. And then repeat the hard way again, because they didn't learn their lesson the first time. Like in March 2020, for example.
We have the chance at this very moment to take the yellow path. If we just shut down right now. Shutting down would prevent what's about to take place.
And what's about to take place?...
The red path or purple path..
The red path sits at 42%.
The purple path sits at 31%.
The yellow safe path sits at 27%, probability.
We MUST flatten the incoming parabola.. or millions more will die globally from the next wave of Covid-19.
But of course, no one will listen until its much too late.
Thanks for Pondering the Unknown with Me.
Stay Safe,
Glitch420
OCGN injectedContinuation play here in my opinion. Can expect this to travel up to around 20$ in the next few weeks. Trade safe! This is a high risk pick...
Please like/share if you want to see more!
